On the one hand, Tc17 responses that may not be cytotoxic are enhanced; on the other hand, under many conditions, tumor antigen-specific T-cell responses may even be enhanced against low-affinity tumor antigens under PD-1 blockade. Here, PDCD1 is linked to neoplasm.